Ionis angioedema drug shows positive results in Phase 3 trial (NASDAQ:IONS)
Ionis Pharmaceuticals (NASDAQ:IONS) on Monday announced positive topline Phase 3 trial results for its donidalorsen drug candidate for hereditary angioedema (HAE). The Phase 3 OASIS-HAE study found donidalorsen met the primary endpoint of…
